Infective endocarditis prevention prior to dental procedures

Chiżyński, Adam; Pawlicka, Halina; Chiżyński, Krzysztof

doi:10.5604/00114553.1007604

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hyperuricemia was diagnosed based on a serum uric acid level greater than or equal to 7.0 mg/dL in men and 6.0 mg/dL in women (Dincer et al, 2002;Chizynski and Rozycka, 2005). Any participant with hypertension (systolic blood pressure > 140 mmHg and diastolic blood pressure > 90 mmHg), lowering serum uric acid agents, or type 2 diabetes in the last 6 months was excluded.…”

Section: Methodsmentioning

confidence: 99%

Gender, Body Mass Index, and PPARγ Polymorphism Are Good Indicators in Hyperuricemia Prediction for Han Chinese

Lee

Liou²,

Wang³

et al. 2013

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Hyperuricemia is closely associated with obesity and metabolic abnormalities, which is also an independent risk factor for cardiovascular diseases. The PPARg gene, which is linked to obesity and metabolic abnormalities in Han Chinese, might be considered a top candidate gene that is involved in hyperuricemia. This study recruited 457 participants, aged 20-40 years old, to investigate the associations of the PPARg gene and metabolic parameters with hyperuricemia. Three tag-single nucleotide polymorphisms, rs2292101, rs4684846, and rs1822825, of the PPARg gene were selected to explore their association with hyperuricemia. Risk genotypes on rs1822825 of the PPARg gene exhibited statistical significance with hyperuricemia (odds ratio: 1.9; 95% confidence interval: 1.05-3.57). Although gender, body mass index (BMI), serum total cholesterol concentration, or protein intake per day were statistically associated with hyperuricemia, the combination of BMI, gender, and rs1822825, rather than that of age, serum lipid profile, blood pressure, and protein intake per day, satisfied the predictability for hyperuricemia (sensitivity: 69.3%; specificity: 83.7%) in Taiwan-born obese Han Chinese. BMI, gender, and the rs1822825 polymorphism in the PPARg gene appeared good biomarkers in hyperuricemia; therefore, these powerful indicators may be included in the prediction of hyperuricemia to increase the accuracy of the analysis.

show abstract

Section: Methodsmentioning

confidence: 99%

Gender, Body Mass Index, and PPARγ Polymorphism Are Good Indicators in Hyperuricemia Prediction for Han Chinese

Lee

Liou²,

Wang³

et al. 2013

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

show abstract

“…Moreover, as compared with other mammals, in humans, defective urease activity results in increased serum uric acid level [2], so humans with purine metabolism disorder are at risk of hyperuricemia. The upper normal range of serum uric acid concentration is 360 µmol/l for women and 400 µmol/l for men [3]. Several clinical epidemiological studies have shown that hyperuricemia has become a prevalent disease worldwide over the past several decades because of improved standard of living [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

High Uric Acid Activates the ROS-AMPK Pathway, Impairs CD68 Expression and Inhibits OxLDL-Induced Foam-Cell Formation in a Human Monocytic Cell Line, THP-1

Luo¹,

Lian

Hong³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Hyperuricemia is part of the metabolic-syndrome cluster of abdominal obesity, impaired glucose tolerance, insulin resistance, dyslipidemia, and hypertension. Monocytes/macrophages are critical in the development of metabolic syndrome, including gout, obesity and atherosclerosis. However, how high uric acid (HUA) exposure affects monocyte/macrophage function remains unclear. In this study, we investigated the molecular mechanism of HUA exposure in monocytes/macrophages and its impact on oxidized low-density lipoprotein (oxLDL)-induced foam-cell formation in a human monocytic cell line, THP-1. Methods: We primed THP-1 cells with phorbol-12-myristate-13-acetate (PMA) for differentiation, then exposed cells to HUA and detected the production of reactive oxygen species (ROS) and analyzed the level of phospho-AMPKα. THP-1 cells were pre-incubated with Compound C, an AMPK inhibitor, or N-acetyl-L-cysteine (NAC), a ROS scavenger, or HUA before PMA, to assess CD68 expression and phospho-AMPKα level. PMA-primed THP-1 cells were pre-treated with oxLDL before Compound C and HUA treatment. Western blot analysis was used to examine the levels of phospho-AMPKα, CD68, ABCG1, ABCA1, cyclooxygenase-2 (COX-2) and NF-κB (p65). Flow cytometry was used to assess ROS production and CD68 expression in live cells. Oil-red O staining was used to observe oxLDL uptake in cells. Results: HUA treatment increased ROS production in PMA-primed THP-1 cells; NAC blocked HUA-induced oxidative stress. HUA treatment time-dependently increased phospho-AMPKα level in PMA-primed THP-1 cells. The HUA-induced oxidative stress increased phospho-AMPKα levels, which was blocked by NAC. HUA treatment impaired CD68 expression during cell differentiation by activating the AMPK pathway, which was reversed by Compound C treatment. Finally, HUA treatment inhibited oxLDL uptake in the formation of foam cells in THP-1 cells, which was blocked by Compound C treatment. HUA treatment significantly increased the expression of ABCG1 and reversed the oxLDL-reduced ABCG1 expression but did not affect the expression of ABCA1, NF-κB (p65) or COX-2. Conclusions: HUA exposure activated the ROS-AMPK pathway, impaired CD68 expression, and inhibited oxLDL-induced foam-cell formation in a human monocytic cell line, THP-1.

show abstract

“…By reducing the incidence of hyperuricemia among the middle-aged and elderly, the risk of these diseases will be delayed and the health and quality of life will be improved [28][29][30]. However, hyperuricemia is seldom recognized as a risk factor that needs to be independently controlled in the diagnosis and treatment of many middle-aged and elderly chronic diseases [19]. As of now, there has only been one study that has studied the relationship between serum uric acid and S-Klotho [32].…”

Section: Introductionmentioning

confidence: 99%

Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people

Xie

Zhou

et al. 2022

Preprint

View full text Add to dashboard Cite

Background:Soluble Klotho (S-Klotho) is an anti-aging protein mainly secreted by the kidneys. Hyperuricemia is prevalent among middle-aged and elderly individuals, which affects the development of various chronic diseases. However, there are relatively few studies investigating the association between plasma S-Klotho levels and hyperuricemia in middle-aged and elderly individuals. This study sought to clarify the relationship between S-Klotho and the risk of hyperuricemia in middle-aged and elderly people.Methods:During 2007-2016, a total of 50,588 people participated in the National Health and Nutrition Examination Survey. Finally, 12,498 middle-aged and elderly people (aged 40-79) completed the soluble Klotho tests and had obtained complete data. S-Klotho was detected by ELISA kit, and the relationship between S-Klotho and hyperuricemia was assessd by multiple logistic regression. Hyperuricemia is defined as serum uric acid levels higher than or equal to 420 mmol/L in men and 360 mmol/L in women.Results:In the middle-aged and elderly, plasma S-Klotho levels were negatively correlated with hyperuricemia, and there was a saturation effect. The inflection point of S-Klotho was 850.9 pg/ml (logarithmic likelihood ratio test <0.001). When plasma S-Klotho <850.9 pg/ml, the prevalence of hyperuricemia in middle-aged and elderly individuals with higher levels of S-Klotho decreased by 27.1% compared with those with low levels of S-Klotho[Q4 vs Q1, OR: 0.729, 95%CI: (0.615, 0.863), P < 0.001]; In different age groups, S-Klotho had a significantly greater effect on hyperuricemia in middle-aged people[Age: 40-65years, Q4 vs Q1, OR(95%CI): 0.64, (0.55, 0.76), P <0.001; Age>65 years: Q4 vs Q1, OR(95%CI): 0.67, (0.53, 0.85), P =0.001)] .When the level of S-Klotho was higher, the risk of hyperuricemia in men was lower than that in women [male: Q4 vs Q1, OR(95%CI): 0.64, (0.53, 0.77), P <0.001; female: Q4 vs Q1 (95%CI):0.66, (0.54, 0.81), P <0.001].Conclusions:In middle-aged and elderly individuals, plasma S-Klotho levels were inversely correlated with hyperuricemia, with a saturation effect. Given the limitations of the research results, the underlying mechanism between S-Klotho and hyperuricemia should be further explored.

show abstract

Infective endocarditis prevention prior to dental procedures

Cited by 4 publications

References 0 publications

Gender, Body Mass Index, and PPARγ Polymorphism Are Good Indicators in Hyperuricemia Prediction for Han Chinese

Gender, Body Mass Index, and PPARγ Polymorphism Are Good Indicators in Hyperuricemia Prediction for Han Chinese

High Uric Acid Activates the ROS-AMPK Pathway, Impairs CD68 Expression and Inhibits OxLDL-Induced Foam-Cell Formation in a Human Monocytic Cell Line, THP-1

Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people

Contact Info

Product

Resources

About